Non-steroidal anti-inflammatory drugs (NSAIDs) are an important class of therapeutics, incorporate a heterocyclic core in
their molecular structure and are used for the alleviation of pain and inflammation associated with several pathological conditions.
NSAIDs exert anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COXs) which, are useful in the synthesis of prostanoids
generated from arachidonic acid. Selective COX-II inhibitors, compared to nonselective inhibitors exhibit reduced gastrointestinal, ulceration
and renal side effects. In general, COX-II inhibitors incorporate a five or six-membered heterocyclic motif with built-in sulfonamide
or methylsulfonate moiety. Celecoxib, a selective COX-II inhibitor drug, commercialized by Pfizer is applied in the treatment
of rheumatoid arthritis, osteoarthritis, and painful menstruation related symptoms. The current review provides a discussion on the methodologies
used to construct celecoxib/celebrex® and structural analogs.
Keywords: Celecoxib, Celebrex®, Pyrazoles, Heterocycles, COX, Cycloadditions, Couplings, and Condensations
open access plus
Rights & PermissionsPrintExport